As the COVID-19 economic war continues, the media seem to have taken their position on potential treatments. We have previously highlighted a potential botanical extract COVID-19 treatment that prevents key viruses from correctly forming their protective “envelope.” Initial results against COVID-19 showed a dramatic 20,000-fold reduction in viral infectivity within 24 hours, with minimal side effects. The compound has already met FDA Phase I and II safety studies with reputable institutions, but it appears testing in a supervised hospital setting has stalled. Normally the media would celebrate a potential COVID-19 breakthrough treatment, but this is different. Andrew Whitney, vice chairman of Phoenix Biotechnology, joins the Economic War Room to share the real data.